Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ORAL ANTIDIABETIC DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL XX SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
6.6 TREATMENT PARADIGM AND OUTLOOK
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DRUG CLASS
14.1 OVERVIEW
14.2 BIGUANIDES (METFORMIN)
14.2.1 BIGUANIDES (METFORMIN), BY TYPE
14.2.1.1. MONOTHERAPY
14.2.1.2. COMBINATION THERAPY
14.2.2 BIGUANIDES, BY DRUG TYPE
14.2.2.1. GENERIC
14.2.2.2. BRANDED
14.2.2.2.1. FORTAMET
14.2.2.2.2. GLUCOPHAGE
14.2.2.2.3. GLUCOPHAGE XR
14.2.2.2.4. GLUMETZA
14.2.2.2.5. RIOMET
14.2.2.2.6. OTHERS (IF ANY)
14.3 THIAZOLIDINEDIONES
14.3.1 THIAZOLIDINEDIONES, BY TYPE
14.3.1.1. ROSIGLITAZONE
14.3.1.2. PIOGLITAZONE
14.3.2 THIAZOLIDINEDIONES, BY DRUG TYPE
14.3.2.1. GENERIC
14.3.2.2. BRANDED
14.3.2.2.1. ACTOS
14.3.2.2.2. AVANDIA
14.3.2.2.3. OTHERS (IF ANY)
14.4 DIPEPTIDYL PEPTIDASE IV INHIBITORS
14.4.1 DIPEPTIDYL PEPTIDASE IV INHIBITORS, BY TYPE
14.4.1.1. SITAGLIPTIN
14.4.1.2. LINAGLIPTIN
14.4.1.3. SAXAGLIPTIN
14.4.1.4. ALOGLIPTIN
14.4.2 DIPEPTIDYL PEPTIDASE IV INHIBITORS, BY DRUG TYPE
14.4.2.1. GENERIC
14.4.2.2. BRANDED
14.4.2.2.1. JANUVIA
14.4.2.2.2. TRADJENTA
14.4.2.2.3. ONGLYZA
14.4.2.2.4. NESINA
14.4.2.2.5. OTHERS (IF ANY)
14.5 Α-GLUCOSIDASE INHIBITORS
14.5.1 A-GLUCOSIDASE INHIBITORS, BY TYPE
14.5.1.1. ACARBOSE
14.5.1.2. MIGLITOL
14.5.2 A-GLUCOSIDASE INHIBITORS, BY DRUG TYPE
14.5.2.1. GENERIC
14.5.2.2. BRANDED
14.5.2.2.1. PRECOSE
14.5.2.2.2. GLYSET
14.5.2.2.3. OTHERS (IF ANY)
14.6 INSULIN SECRETAGOGUES
14.6.1 SULFONYLUREAS
14.6.1.1. SULFONYLUREAS, BY TYPE
14.6.1.1.1. FIRST GENERATION
14.6.1.1.1.1 ACETOHEXAMIDE
14.6.1.1.1.2 CHLORPROPAMIDE
14.6.1.1.1.3 TOLAZAMIDE
14.6.1.1.1.4 TOLBUTAMIDE
14.6.1.1.2. SECOND GENERATION
14.6.1.1.2.1 GLIPIZIDE
14.6.1.1.2.2 GLYBURIDE
14.6.1.1.2.3 GLICLAZIDE
14.6.1.1.2.4 GLIMEPIRIDE
14.6.1.2. SULFONYLUREAS, BY DRUG TYPE
14.6.1.2.1. GENERIC
14.6.1.2.2. BRANDED
14.6.1.2.2.1 DIAMICRON
14.6.1.2.2.2 GLIBENESE
14.6.1.2.2.3 AMARYL
14.6.1.2.2.4 GLYNASE
14.6.1.2.2.5 OTHERS (IF ANY)
14.6.2 GLINIDES
14.6.2.1. GLINIDES, BY TYPE
14.6.2.1.1. REPAGLINIDE
14.6.2.1.2. NATEGLINIDE
14.6.2.2. GLINIDES, BY DRUG TYPE
14.6.2.2.1. GENERIC
14.6.2.2.2. BRANDED
14.6.2.2.2.1 PRANDIN
14.6.2.2.2.2 STARLIX
14.6.2.2.2.3 OTHERS (IF ANY)
14.7 SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS
14.7.1 SGLT2 INHIBITORS, BY TYPE
14.7.1.1. CANAGLIFLOZIN
14.7.1.2. DAPAGLIFLOZIN
14.7.1.3. EMPAGLIFLOZIN
14.7.1.4. OTHERS (IF ANY)
14.7.2 SGLT2 INHIBITORS, BY DRUG TYPE
14.7.2.1. GENERIC
14.7.2.2. BRANDED
14.7.2.2.1. FORXIGO
14.7.2.2.2. INVOKANA
14.7.2.2.3. BRENZAVVY
14.7.2.2.4. JARDIANCE
14.7.2.2.5. STEGLATRO
14.7.2.2.6. OTHERS (IF ANY)
14.8 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
14.9 OTHERS
14.9.1 COMBINATION DRUGS
14.9.1.1. COMBINATION DRUGS, BY TYPE
14.9.1.1.1. ALOGLIPTIN/METFORMIN
14.9.1.1.2. CANAGLIFLOZIN/METFORMIN
14.9.1.1.3. DAPAGLIFLOZIN/METFORMIN
14.9.1.1.4. DAPAGLIFLOZIN/METFORMIN/SAXAGLIPTIN
14.9.1.1.5. EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN
14.9.1.1.6. EMPAGLIFLOZIN/METFORMIN
14.9.1.1.7. ERTUGLIFLOZIN/METFORMIN
14.9.1.1.8. GLIPIZIDE/METFORMIN
14.9.1.1.9. GLYBURIDE/METFORMIN
14.9.1.1.10. LINAGLIPTIN/METFORMIN
14.9.1.1.11. METFORMIN/PIOGLITAZONE
14.9.1.1.12. METFORMIN/ROSIGLITAZONE
14.9.1.1.13. METFORMIN/REPAGLINIDE
14.9.1.1.14. OTHERS
14.9.1.2. COMBINATION DRUGS, BY DRUG TYPE
14.9.1.2.1. GENERIC
14.9.1.2.2. BRANDED
14.9.1.2.2.1 KAZANO
14.9.1.2.2.2 INVOKAMET
14.9.1.2.2.3 XIGDUO XR
14.9.1.2.2.4 QTERNMET XR
14.9.1.2.2.5 TRIJARDY XR
14.9.1.2.2.6 SYNJARDY
14.9.1.2.2.7 SEGLUROMET
14.9.1.2.2.8 METAGLIP
14.9.1.2.2.9 GLUCOVANCE
14.9.1.2.2.10 JENTADUETO
14.9.1.2.2.11 JENTADUETO XR
14.9.1.2.2.12 ACTOPLUS MET
14.9.1.2.2.13 PRANDIMET
14.9.1.2.2.14 AVANDAMET
14.9.1.2.2.15 KOMBIGLYZE XR
14.9.1.2.2.16 OTHERS
14.9.2 OTHERS (IF ANY)
15 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DRUG TYPE
15.1 OVERVIEW
15.2 BRANDED
15.2.1 FORTAMET
15.2.2 GLUCOPHAGE
15.2.3 GLUCOPHAGE XR
15.2.4 GLUMETZA
15.2.5 RIOMET
15.2.6 FORXIGO
15.2.7 INVOKANA
15.2.8 BRENZAVVY
15.2.9 JARDIANCE
15.2.10 STEGLATRO
15.2.11 PRANDIN
15.2.12 STARLIX
15.2.13 DIAMICRON
15.2.14 GLIBENESE
15.2.15 AMARYL
15.2.16 GLYNASE
15.2.17 OTHERS
15.3 GENERIC
16 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY ACTIVITY
16.1 OVERVIEW
16.2 EXTENDED RELEASE
16.3 IMMEDIATE RELEASE
17 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DIABETES TYPE
17.1 OVERVIEW
17.2 TYPE 1 DIABETES
17.3 TYPE 2 DIABETES
17.4 GESTATIONAL DIABETES
18 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY REGIMENS
18.1 OVERVIEW
18.2 MONTHERAPY
18.3 COMBINATION THERAPY
19 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY POPULATION TYPE
19.1 OVERVIEW
19.2 PEDIATRIC
19.2.1 BY GENDER
19.2.1.1. MALE
19.2.1.2. FEMALE
19.3 ADULTS
19.3.1 BY GENDER
19.3.1.1. MALE
19.3.1.2. FEMALE
19.4 GERIATRIC
19.4.1 BY GENDER
19.4.1.1. MALE
19.4.1.2. FEMALE
20 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.2.1 BY TYPE
20.2.1.1. PRIVATE
20.2.1.1.1. BY TIER
20.2.1.1.1.1 TIER I
20.2.1.1.1.2 TIER II
20.2.1.1.1.3 TIER III
20.2.1.2. PUBLIC
20.2.1.2.1. BY TIER
20.2.1.2.1.1 TIER I
20.2.1.2.1.2 TIER II
20.2.1.2.1.3 TIER III
20.3 HOME HEALTHCARE
20.4 SPECIALTY CENTERS
20.5 DIABETES CARE CENTERS
20.6 AMBULATORY CENTERS
20.7 OTHERS
21 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL SALES
21.3.1 HOSPITAL PHARMACY
21.3.2 RETAIL PHARMACY
21.3.3 ONLINE PHARMACY
21.4 OTHERS
22 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, SWOT AND DBMR ANALYSIS
23 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 NEW PRODUCT DEVELOPMENT & APPROVALS
23.7 EXPANSIONS
23.8 REGULATORY CHANGES
23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY REGION
GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 NORTH AMERICA
24.1.1 U.S.
24.1.2 CANADA
24.1.3 MEXICO
24.2 EUROPE
24.2.1 GERMANY
24.2.2 U.K.
24.2.3 ITALY
24.2.4 FRANCE
24.2.5 SPAIN
24.2.6 RUSSIA
24.2.7 SWITZERLAND
24.2.8 TURKEY
24.2.9 BELGIUM
24.2.10 NETHERLANDS
24.2.11 DENMARK
24.2.12 SWEDEN
24.2.13 POLAND
24.2.14 NORWAY
24.2.15 FINLAND
24.2.16 REST OF EUROPE
24.3 ASIA-PACIFIC
24.3.1 JAPAN
24.3.2 CHINA
24.3.3 SOUTH KOREA
24.3.4 INDIA
24.3.5 SINGAPORE
24.3.6 THAILAND
24.3.7 INDONESIA
24.3.8 MALAYSIA
24.3.9 PHILIPPINES
24.3.10 AUSTRALIA
24.3.11 NEW ZEALAND
24.3.12 VIETNAM
24.3.13 TAIWAN
24.3.14 REST OF ASIA-PACIFIC
24.4 SOUTH AMERICA
24.4.1 BRAZIL
24.4.2 ARGENTINA
24.4.3 REST OF SOUTH AMERICA
24.5 MIDDLE EAST AND AFRICA
24.5.1 SOUTH AFRICA
24.5.2 EGYPT
24.5.3 BAHRAIN
24.5.4 UNITED ARAB EMIRATES
24.5.5 KUWAIT
24.5.6 OMAN
24.5.7 QATAR
24.5.8 SAUDI ARABIA
24.5.9 REST OF MEA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, COMPANY PROFILE
25.1 PFIZER INC.
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 NOVARTIS
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 TEVA PHARMACEUTICALS USA, INC.
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 ASTRAZENECA
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 BAYER AG
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 SANOFI
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 ASTELLAS PHARMA INC.
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC.
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 NOVO NORDISK A/S
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 MERCK & CO., INC.
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 GSK PLC.
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 AJANTA PHARMAC INC.
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 LUPIN
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 AMNEAL PHARMACEUTICALS INC.
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 LES LABORATORIES SERVIER
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 ADVACARE PHARMA
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 WELLONA PHARMA
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
25.19 THERACOSBIO, LLC
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENTS
25.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENTS
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
